Table 1 Bias evaluation of included studies
From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
Study ID | Author | Domains | Reviewers observations | ||||
|---|---|---|---|---|---|---|---|
Random sequence generation | Allocation Blinding | Participants and people blinding | Evaluators and outcome blinding | Incomplete outcome data | |||
Method described with detail | Investigative personnel was blind to allocation | Blinding method for participants and personnel was effective? | Blinding method for the study evaluators was effective? | Main outcomes, fall outs, exclusions, number, in each intervention group, reason for losses and changes in plan analysis | |||
1 | Maurer et al., 2011 [20] | Random sequence by validated system 1:1 | Similar packages and presentation between placebo and intervention | Yes | Yes | Yes | - |
2 | Saini et al., 2011 [21] | Sequence 1:1:1:1 | Similar packages and presentation between placebo and intervention | Yes | Yes | Yes | - |
3 | Maurer et al., 2013 [19] | Sequence 1:1:1:1 by voice interactive service | Similar packages and presentation between placebo and intervention | Yes | Yes | Yes | Blind in each center, drug not blinded but person administering the drug is blinded |
4 | Kaplan et al., 2013 [22] | 3:1 stratified by itch severity score (ISS) and baseline weight | Similar packages and presentation between placebo and intervention | Yes | Yes | Yes | Person who prepared the drug was not blinded, but the one administering the drug was blinded |
5 | Saini et al., 2014 [23] | Sequence 1:1:1:1 stratified by weekly ISS, baseline weight (< or ?80 kg) and study center by interactive voice and web response system | Not specified in the article but the clinicaltrials.gov register specified the similar packages between placebo and intervention | Yes | Yes | Yes | Person who prepared the drug was not blinded but did not interact with patients |